SouthernWorldwide.com – Researchers have uncovered a potential new avenue for treating alcohol withdrawal, suggesting that an experimental Alzheimer’s drug could help mitigate the damage associated with this condition.
The drug, known as MW150, is currently under investigation for its ability to calm brain inflammation. This inflammation is believed to play a significant role in addiction and the risk of relapse.
The research was conducted by scientists at the University of Kentucky. Their work focused on MW150’s mechanism, which targets a specific brain inflammation pathway called p38α MAPK. This pathway is implicated in various neurological conditions.
MW150 is not yet approved for any medical use. Its primary development has been as a potential treatment for mild to moderate Alzheimer’s disease. The drug aims to address the neurodegenerative processes characteristic of this condition.
Recent years have seen a concerning rise in alcohol-related deaths, with a particularly sharp increase observed among women. This trend underscores the urgent need for effective interventions in alcohol use disorder.
Scientists hypothesize that neuroinflammation contributes to the challenges faced by individuals with alcohol use disorder. This inflammation is thought to increase the likelihood of relapse and can lead to long-term damage to the nervous system.
Initial experiments conducted in laboratory settings and using animal models showed promising results. MW150 was observed to reduce specific markers of inflammation during the alcohol withdrawal phase.
The findings of this research were published in the journal *Alcohol*. The study originated from the University of Kentucky’s Sanders-Brown Center on Aging, with neuroinflammation researcher Linda Van Eldik leading the effort.
Caleb Bailey, PhD, a co-author of the study and a researcher in Van Eldik’s lab, commented on the significance of their findings. He stated that the study provides “biological plausibility” for MW150’s ability to lessen neuroinflammation that arises from alcohol withdrawal.
Alcohol use disorder is notoriously difficult to treat, largely due to high relapse rates. Bailey highlighted that these relapse rates are particularly prevalent during the withdrawal period.
The experimental drug MW150, along with a similar compound named Neflamapimod, is already being explored in clinical trials. These trials are investigating their potential as therapies for dementia and other neurodegenerative diseases.
Bailey noted that this ongoing development for other neurological conditions adds weight to their current research. If future studies continue to show positive results, the existing progress in developing these compounds could expedite their repurposing for alcohol-related conditions.
However, the researchers acknowledged important limitations to their current work. A key caveat is that the experiments were primarily conducted in cell cultures and animal models.
Bailey explained that “dish”-based models offer limited insights into the complex processes occurring within a whole organism, or even a complete brain. Therefore, further investigation is crucial.
A series of follow-up studies involving living animals is necessary. These studies will aim to provide a more comprehensive understanding of how MW150 treatment might affect systemic health and alcohol consumption in the context of alcohol use and withdrawal.
Dr. Amy Swift, deputy chief medical officer at Silver Hill Hospital in Connecticut, who was not involved in the study, shared her perspective on the findings. She emphasized the distinction between detoxification and treating the disorder itself.
Swift clarified that detoxification primarily serves to prevent potentially fatal complications associated with alcohol withdrawal. It does not, by itself, address the underlying alcohol use disorder.
She suggested that the addition of supportive medications could fill a significant gap in the early stages of detoxification treatment. Medications aimed at improving overall brain health could be particularly beneficial.
Given the widespread inflammatory effects of alcohol on various organ systems, Swift believes it is worthwhile to explore whether reducing neuroinflammation could enhance a patient’s engagement with treatment. Earlier engagement could potentially lead to a more meaningful and lasting change in their relationship with alcohol.
Bailey reiterated that from a physical health perspective, no level of alcohol consumption is considered beneficial. This is a fundamental principle in public health advice regarding alcohol.
He pointed out that currently, there are no robust pharmacological treatments available to effectively mitigate the damage caused by chronic alcohol consumption. Therefore, minimizing alcohol intake remains the most effective strategy for maintaining good health.
Read more : Marine Vet Prosecutor Won't Cross Constitutional Line on Spanberger 'Assault Weapon' Ban
As the research into MW150 for dementia patients progresses, Bailey emphasized the importance of gathering information on how these drugs interact with alcohol. Understanding these interactions, whether positive or negative, will be critical for determining patient outcomes in the future.
